A normal echocardiogram doesn't always mean a healthy heart. Persistent symptoms like breathlessness and fatigue can indicate ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

There may be a future for cardiac myosin inhibitors in heart failure with preserved ejection fraction (HFpEF), according to the proof-of-concept EMBARK-HFpEF trial. An established cardiac myosin ...

The Heart Failure Society of America (HFSA), the Heart Failure Association of the European Society of Cardiology (HFA of the ESC), and the Japanese Heart Failure Society (JHFS) announced today a new ...

Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a ...

HFpEF and HFmrEF represent up to 75% of heart failure cases, yet treatment evidence is limited compared to other heart failure types. The IMPLEMENT-EF initiative aims to map patient journeys, address ...

Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.